HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells

Biochemical and Biophysical Research Communications

Volumn 324, Issue 1, 2004, Pages 8-14

  Ammerpohl, Ole ^a   Thormeyer, Dorit ^a   Khan, Zahidul ^a   Appelskog, Ioulia B ^a   Gojkovic, Zoran ^b   Almqvist, Per M ^a,c   Ekström, Tomas J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ZGene AS   (Denmark)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

4 Phenylbutyrate; Bystander killing; Ganciclovir; Gap junction; Glioma; HDAC inhibitor; HSV tk

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; GANCICLOVIR; HERPESVIRUS VECTOR; HISTONE DEACETYLASE INHIBITOR; RECOMBINANT PROTEIN; THYMIDINE KINASE;

ANIMAL CELL; ARTICLE; BYSTANDER EFFECT; CANCER ADJUVANT THERAPY; CELL COMMUNICATION; CELL KILLING; CONTROLLED STUDY; DRUG POTENTIATION; GAP JUNCTION; GENE ACTIVATION; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; NONHUMAN; PRIORITY JOURNAL; RAT; SUICIDE GENE THERAPY; TUMOR CELL; VIRUS RECOMBINANT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; BYSTANDER EFFECT; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CONNEXIN 43; GANCICLOVIR; GAP JUNCTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GLIOMA; GLYCYRRHETINIC ACID; HISTONE DEACETYLASES; HUMANS; PHENYLBUTYRATES; RATS; RECOMBINANT FUSION PROTEINS; SIMPLEXVIRUS; THYMIDINE KINASE;

ANIMALIA;

EID: 4744370942     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.09.016     Document Type: Article

References (40)

1. W.A. Denny Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy) J. Biomed. Biotechnol. 2003 2003 48 70
2. T. Kanzawa, H. Ito, Y. Kondo, and S. Kondo Current and future gene therapy for malignant gliomas J. Biomed. Biotechnol. 2003 2003 25 34
3. R. Bruzzone, T.W. White, and D.L. Paul Connections with connexins: the molecular basis of direct intercellular signaling Eur. J. Biochem. 238 1996 1 27
4. M.V. Bennett, J.E. Contreras, F.F. Bukauskas, and J.C. Saez New roles for astrocytes: gap junction hemichannels have something to communicate Trends Neurosci. 26 2003 610 617
5. H. Yamasaki, and C.C. Naus Role of connexin genes in growth control Carcinogenesis 17 1996 1199 1213
6. T. Sakatani, and P. Onyango Oncogenomics: prospects for the future Expert Rev. Anticancer Ther. 3 2003 891 901
7. L.L. Oligny Cancer and epigenesis: a developmental perspective Adv. Pediatr. 50 2003 59 80
8. L. Kopelovich, J.A. Crowell, and J.R. Fay The epigenome as a target for cancer chemoprevention J. Natl. Cancer Inst. 95 2003 1747 1757
9. S.G. Gray, and T.J. Ekström The human histone deacetylase family Exp. Cell Res. 262 2001 75 83
10. J.S. Chen, D.V. Faller, and R.A. Spanjaard Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr. Cancer Drug Targets 3 2003 219 236
11. D.H. Kim, M. Kim, and H.J. Kwon Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents J. Biochem. Mol. Biol. 36 2003 110 119
12. D.M. Vigushin, and R.C. Coombes Histone deacetylase inhibitors in cancer treatment Anticancer Drugs 13 2002 1 13
13. M. Yoshida, R. Furumai, M. Nishiyama, Y. Komatsu, N. Nishino, and S. Horinouchi Histone deacetylase as a new target for cancer chemotherapy Cancer Chemother. Pharmacol. 48 Suppl. 1 2001 S20 S26
14. M. Jung Inhibitors of histone deacetylase as new anticancer agents Curr. Med. Chem. 8 2001 1505 1511
15. D. Hoelzer, and N. Gokbuget New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin. Oncol. 27 2000 540 559
16. P.A. Marks, V.M. Richon, and R.A. Rifkind Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J. Natl. Cancer Inst. 92 2000 1210 1216
17. I. Svechnikova, S.G. Gray, J. Kundrotiene, F. Ponthan, P. Kogner, and T.J. Ekström Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate Int. J. Oncol. 22 2003 579 588
18. S. Yamamoto, T. Yamano, M. Tanaka, D.S. Hoon, S. Takao, R. Morishita, T. Aikou, and Y. Kaneda A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma Cancer Gene Ther. 10 2003 179 186
19. T. Asklund, I.B. Appelskog, O. Ammerpohl, T.J. Ekström, and P.M. Almqvist Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells Eur. J. Cancer 40 2004 1073 1081
20. T. Asklund, I.B. Appelskog, O. Ammerpohl, I.A. Langmoen, M.S. Dilber, A. Aints, T.J. Ekström, and P.M. Almqvist Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene Exp. Cell Res. 284 2003 185 195
21. S.P. Cole Rapid chemosensitivity testing of human lung tumor cells using the MTT assay Cancer Chemother. Pharmacol. 17 1986 259 263
22. M.S. Mahaley Jr., C. Mettlin, N. Natarajan, E.R. Laws Jr., and B.B. Peace National survey of patterns of care for brain-tumor patients J. Neurosurg. 71 1989 826 836
23. T.W. Trask, R.P. Trask, E. Aguilar-Cordova, H.D. Shine, P.R. Wyde, J.C. Goodman, W.J. Hamilton, A. Rojas-Martinez, S.H. Chen, S.L. Woo, and R.G. Grossman Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors Mol. Ther. 1 2000 195 203
24. B.M. Colombo, S. Benedetti, S. Ottolenghi, M. Mora, B. Pollo, G. Poli, and G. Finocchiaro The "bystander effect": association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice Hum. Gene Ther. 6 1995 763 772
25. M. Izquierdo, V. Martin, P. de Felipe, J.M. Izquierdo, A. Perez-Higueras, M.L. Cortes, J.F. Paz, A. Isla, and M.G. Blazquez Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy Gene Ther. 3 1996 491 495
26. H. Okada, K. Miyamura, T. Itoh, M. Hagiwara, T. Wakabayashi, M. Mizuno, P. Colosi, G. Kurtzman, and J. Yoshida Gene therapy against an experimental glioma using adeno-associated virus vectors Gene Ther. 3 1996 957 964
27. D. Klatzmann, C.A. Valery, G. Bensimon, B. Marro, O. Boyer, K. Mokhtari, B. Diquet, J.L. Salzmann, and J. Philippon A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study group on gene therapy for glioblastoma Hum. Gene Ther. 9 1998 2595 2604
28. N. Shand, F. Weber, L. Mariani, M. Bernstein, A. Gianella-Borradori, Z. Long, A.G. Sorensen, and N. Barbier A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group Hum. Gene Ther. 10 1999 2325 2335
29. C.A. Kruse, C. Lamb, S. Hogan, W.R. Smiley, B.K. Kleinschmidt-Demasters, and F.J. Burrows Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms Cancer Gene Ther. 7 2000 118 127
30. A.M. Sandmair, S. Loimas, P. Puranen, A. Immonen, M. Kossila, M. Puranen, H. Hurskainen, K. Tyynela, M. Turunen, R. Vanninen, P. Lehtolainen, L. Paljarvi, R. Johansson, M. Vapalahti, and S. Yla-Herttuala Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses Hum. Gene Ther. 11 2000 2197 2205
31. F.W. Floeth, N. Shand, H. Bojar, H.B. Prisack, J. Felsberg, E. Neuen-Jacob, A. Aulich, K.J. Burger, W.J. Bock, and F. Weber Local inflammation and devascularization - in vivo mechanisms of the "bystander effect" in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma Cancer Gene Ther. 8 2001 843 851
32. S. Moriuchi, D. Wolfe, M. Tamura, T. Yoshimine, F. Miura, J.B. Cohen, and J.C. Glorioso Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model Gene Ther. 9 2002 584 591
33. E. De Clercq, G. Andrei, R. Snoeck, L. De Bolle, L. Naesens, B. Degreve, J. Balzarini, Y. Zhang, D. Schols, P. Leyssen, C. Ying, and J. Neyts Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents Nucleosides Nucleotides Nucleic Acids 20 2001 271 285
34. L.Z. Rubsam, B.L. Davidson, and D.S. Shewach Superior cytotoxicity with ganciclovir compared with acyclovir and 1-beta-d-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing Cancer Res. 58 1998 3873 3882
35. R.P. Huang, Y. Fan, M.Z. Hossain, A. Peng, Z.L. Zeng, and A.L. Boynton Reversion of the neoplastic phenotype of human glioblastoma cells by connexin 43 (cx43) Cancer Res. 58 1998 5089 5096
36. M. Mesnil, and H. Yamasaki Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication Cancer Res. 60 2000 3989 3999
37. J. Fick, F.G. Barker 2nd, P. Dazin, E.M. Westphale, E.C. Beyer, and M.A. Israel The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro Proc. Natl. Acad. Sci. USA 92 1995 11071 11075
38. C. Denning, and J.D. Pitts Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes Hum. Gene Ther. 8 1997 1825 1835
39. A.R. Kianmanesh, H. Perrin, Y. Panis, M. Fabre, H.J. Nagy, D. Houssin, and D. Klatzmann A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor Hum. Gene Ther. 8 1997 1807 1814
40. P.A. Robe, O. Jolois, M. N'Guyen, F. Princen, B. Malgrange, M.P. Merville, and V. Bours Modulation of the HSV-TK/ganciclovir bystander effect by n-butyrate in glioblastoma: correlation with gap-junction intercellular communication Int. J. Oncol. 25 2004 187 192